Marlborough insulin delivery company CeQur has named medtech veteran Bradley Paddock as its new CEO.
Paddock has held key management, executive or sales positions at several large medical device manufacturers, including Kyphon, Stryker, Medtronic and Johnson & Johnson.
In a press release announcing his new position, CeQur said his eight years of work as vice president of U.S. sales at Kyphon led to $600 million in sales and ultimately a $4.2-billion acquisition by Medtronic.
“We believe that this accomplishment, in addition to his impressive history developing commercial organizations, will ensure that CeQur is best placed for rapid development ahead of our launch of the PAQ MEAL insulin delivery device in early 2020,” Executive Chairman Eric Milledge said in a statement.
According to the company, the PAQ product is an insulin patch providing three days of injection-free sugar control. The PAQ MEAL patch provides on-demand mealtime insulin delivery.
Robert Farra, the company’s CEO since November 2016, will move into a new role as chief technology officer.
Neither the PAQ MEAL device or PAQ Total device are commercially available.
